Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 385.69M | 338.46M | 291.49M | 251.02M | 270.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 385.69M | 338.46M | 291.49M | 251.02M | 270.60M |
| Cost of Revenue | 33.30M | 30.17M | 28.26M | 24.81M | 26.07M |
| Gross Profit | 352.39M | 308.29M | 263.23M | 226.22M | 244.54M |
| SG&A Expenses | 411.36M | 384.90M | 372.52M | 347.90M | 323.12M |
| Depreciation & Amortization | 6.39M | 6.39M | 6.39M | 6.39M | 6.38M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 638.13M | 584.33M | 553.43M | 496.08M | 453.51M |
| Operating Income | -252.44M | -245.87M | -261.94M | -245.06M | -182.91M |
| Income Before Tax | -287.13M | -311.28M | -309.56M | -298.00M | -238.28M |
| Income Tax Expenses | 85.00K | -325.00K | -1.00M | -1.62M | 960.00K |
| Earnings from Continuing Operations | -287.22 | -310.96 | -308.55 | -296.38 | -239.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -287.22M | -310.96M | -308.55M | -296.38M | -239.24M |
| EBIT | -252.44M | -245.87M | -261.94M | -245.06M | -182.91M |
| EBITDA | -244.48M | -238.25M | -254.63M | -238.17M | -176.07M |
| EPS Basic | -6.00 | -6.54 | -6.51 | -6.38 | -5.20 |
| Normalized Basic EPS | -3.38 | -3.30 | -3.51 | -3.38 | -2.58 |
| EPS Diluted | -6.00 | -6.54 | -6.51 | -6.38 | -5.20 |
| Normalized Diluted EPS | -3.38 | -3.30 | -3.51 | -3.38 | -2.58 |
| Average Basic Shares Outstanding | 191.65M | 190.44M | 189.41M | 185.51M | 181.64M |
| Average Diluted Shares Outstanding | 191.65M | 190.44M | 189.41M | 185.51M | 181.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
